Dapsone hydroxylamine inhibits the LTB4-induced chemotaxis of polymorphonuclear leukocytes into human skin: Results of a pilot study

Inflammation Research

Volumn 46, Issue 10, 1997, Pages 420-422

  Wozel, G ^a   Blasum, C ^a   Winter, C ^a   Gerlach, B ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Chemotaxis; Dapsone metabolites; LTB4; Polymorphonuclear leukocytes; Skin

Indexed keywords

CLOBETASOL; DAPSONE; ELASTASE; LEUKOTRIENE B4; N HYDROXYDAPSONE;

ADULT; ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FLUOROMETRY; HUMAN; HUMAN EXPERIMENT; MALE; NEUTROPHIL CHEMOTAXIS; NORMAL HUMAN; SKIN BIOPSY; SKIN INFLAMMATION; TOPICAL DRUG ADMINISTRATION;

ADULT; CHEMOTAXIS, LEUKOCYTE; DAPSONE; FEMALE; HUMANS; LEUKOTRIENE B4; MALE; NEUTROPHILS; PILOT PROJECTS; SKIN;

EID: 0030701554     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/s000110050215     Document Type: Conference Paper

References (10)

1. Bernstein JE, Lorine AL. Sulfonamides and sulfones in dermatologic therapy. Int J Dermatol 1981;20:81-8.
2. Wozel G. Dapson - Pharmakologie, Wirkungsmechanismus und klinischer Einsatz. Stuttgart: Thieme, 1996;40-3.46.54-63.
3. Beumont MG, Graziani A, Ubel PA. MacGregor R. Safety of dapsone as Pneumocystis carinii pneumonia prophylaxis in human immunodeficiency virus-infected patients with allergy to trimethoprim/sulfomethoxazole. Am J Med 1996;100:611-6.
4. Zuidema J, Hilbers-Modderman ESM, Merkus FWHM. Clinical pharmacokinetics of dapsone. Clin Pharmacokinet 1986; 11:299-315.
5. Lammers AM, van de Kerkhof PCM, Schalkwijk J, Pier PD. Elastase, a marker for polymorphonuclear leukocytes in skin infiltrates. Br J Dermatol 1986;115:181-186.
6. Chang A, van de Kerkhof PCM. PUVA and UVB inhibit the intra-epidermal accumulation of polymorphonuclear leukocytes. Br J Dermatol 1988;119:281-7.
7. Chang A, van de Kerkhof PCM. Topical application of clobetasol-17-propionate inhibits the intra-epidermal accumulation of polymorphonuclear leukocytes. Acta Derm Venerol 1988;68:57-60.
8. Coleman MD. Dapsone: Modes of action, toxicity and possible strategies for increasing patients. Br J Dermatol 1993;129:507-513.
9. Wozel G, Barth J. Current aspects of modes of action of dapsone. Int J Dermatol 1988;27:547-52.
10. Uetrecht J, Zehid NH, Shear WD, Biggar WD. Metabolism of dapsone to a hydroxylamine by human neutrophils and mononuclear cells. J Pharmacol Exp Ther 1988;245:274-279.